Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Commerzbank interest rate strategist Hauke Siemssen stated in a report that the expected slowing UK inflation data should set the tone for this morning’s bond market, while oil prices remain dominant. He pointed out that ongoing strikes between the US and Iran, along with Houthi threats to Red Sea shipping, have driven Brent crude oil prices back up to $92 per barrel, prompting a bearish market trend. However, he added that “if this morning’s UK inflation data shows a decrease, it may bring a m

Commerzbank interest rate strategist Hauke Siemssen stated in a report that the expected slowing UK inflation data should set the tone for this morning’s bond market, while oil prices remain dominant. He pointed out that ongoing strikes between the US and Iran, along with Houthi threats to Red Sea shipping, have driven Brent crude oil prices back up to $92 per barrel, prompting a bearish market trend. However, he added that “if this morning’s UK inflation data shows a decrease, it may bring a m

智通财经智通财经2026/07/22 06:11
Show original
Commerzbank interest rate strategist Hauke Siemssen stated in a report that the expected slowdown in UK inflation data should set the tone for the bond market this morning, while oil prices remain dominant. He noted that as strikes between the US and Iran continue and Houthi forces threaten Red Sea shipping, Brent crude oil prices have risen again to $92 per barrel, which is driving a bearish market trend. However, "if the UK inflation data released this morning shows a decline, it could result in a more moderate market tone."
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds